TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16487230

Group type: EXPERIMENTAL
Intervention: Course in cognitive therapeutic skills (5th year training copy)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group (normal curriculum)
Number of subjects: 85
Study: 12713193

Group type: EXPERIMENTAL
Intervention: Living with both biological parents
Number of subjects: 34001

Group type: EXPERIMENTAL
Intervention: Living with a single mother
Number of subjects: 34001

Group type: EXPERIMENTAL
Intervention: National beer sales figures and societal patterns of heavy adolescent alcohol use
Number of subjects: 34001
Study: 10859283

Group type: EXPERIMENTAL
Intervention: abciximab-reteplase 5+5 U
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: abciximab-reteplase 5+5 U with 60 U/kg heparin
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: abciximab-reteplase 5+5 U with 40 U/kg heparin
Number of subjects: 241

Group type: COMPARATOR
Intervention: reteplase alone
Number of subjects: 241

Group type: COMPARATOR
Intervention: abciximab alone
Number of subjects: 241

Group type: COMPARATOR
Intervention: standard-dose heparin
Number of subjects: 241

Group type: COMPARATOR
Intervention: low-dose heparin
Number of subjects: 241
Study: 9168578

Group type: EXPERIMENTAL
Intervention: 60 mg aspirin daily
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 8247594

Group type: EXPERIMENTAL
Intervention: Glucomannan (1 g twice a day for two months)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Glucomannan
Number of subjects: 60
Study: 3756056

Group type: EXPERIMENTAL
Intervention: Total i.v. anaesthetic based on etomidate plus increments of fentanyl
Number of subjects: 55

Group type: COMPARATOR
Intervention: Inhaled nitrous oxide with i.v. fentanyl increments
Number of subjects: 55
Study: 31987231

Group type: EXPERIMENTAL
Intervention: Curcumin (500 mg)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Vitamin E (200 IU/day)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Curcumin and Vitamin E
Number of subjects: 93
Study: 29371379

Group type: EXPERIMENTAL
Intervention: PRP+IMT
Number of subjects: 150

Group type: COMPARATOR
Intervention: PRP
Number of subjects: 150
Study: 27253380

Group type: EXPERIMENTAL
Intervention: Medication review intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Factors influencing acceptance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Longitudinal patient care with repeated reviews
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Morbidity and low kidney function
Number of subjects: 0
Study: 24629504

Group type: EXPERIMENTAL
Intervention: Educational intervention for managing fatigue over 3 weeks
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 160
Study: 23046525

Group type: EXPERIMENTAL
Intervention: Dalteparin 50 IU/kg
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Dalteparin 100 IU/kg
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Dalteparin 150 IU/kg
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Dalteparin
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group not applicable
Number of subjects: 77
Study: 20157745

Group type: EXPERIMENTAL
Intervention: 60 mg raloxifene and 1 microg alfacalcidol (RA)/day
Number of subjects: 24

Group type: COMPARATOR
Intervention: 1 microg alfacalcidol alone (A)/day
Number of subjects: 24
Study: 18601844

Group type: EXPERIMENTAL
Intervention: Single Chinese herbal medicine‐based intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Active compound‐based TCM drug intervention
Number of subjects: 0
Study: 16164451

Group type: EXPERIMENTAL
Intervention: Skin prick test (SPT)
Number of subjects: 385
Study: 12515836

Group type: EXPERIMENTAL
Intervention: Dexamphetamine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 11758061

Group type: EXPERIMENTAL
Intervention: Robotically assisted CABG of the left internal thoracic artery (LITA) to the left anterior descending artery (LAD)
Number of subjects: 18
Study: 8672388

Group type: EXPERIMENTAL
Intervention: 3 vol% sevoflurane
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 1.8 vol% isoflurane
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 1.0 vol% sevoflurane
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 2.0 vol% sevoflurane
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 0.6 vol% isoflurane
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 1.2 vol% isoflurane
Number of subjects: 52
Study: 1378646

Group type: EXPERIMENTAL
Intervention: 5 mg nomegestrol acetate combined with 17-beta-estradiol by transcutaneous route
Number of subjects: 0
Study: 6389217

Group type: EXPERIMENTAL
Intervention: Hydrocortisone 17-butyrate (Locoid) 0.1% cream
Number of subjects: 40

Group type: COMPARATOR
Intervention: Hydrocortisone (Uniderm) 1% cream
Number of subjects: 40
Study: 29685482

Group type: EXPERIMENTAL
Intervention: Personalized physical therapy
Number of subjects: 220
Study: 30463763

Group type: EXPERIMENTAL
Intervention: Short Roux loop (SRLG)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Long Roux loop (LRLG)
Number of subjects: 166
Study: 26848872

Group type: EXPERIMENTAL
Intervention: Intervention group (training on injury prevention strategies)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (no specific intervention)
Number of subjects: 55
Study: 25184864

Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine (IIV3)
Number of subjects: 2310

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2310
Study: 22276647

Group type: EXPERIMENTAL
Intervention: Diet with highest nutrient concentration (palm toco concentrate and algae biomass containing astaxanthin)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Diet with highest nutrient concentration
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Arrhenius accelerated stability study
Number of subjects: 4
Study: 20408890

Group type: EXPERIMENTAL
Intervention: Complete immunization schedule with commercial vaccines
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: HAART interruption
Number of subjects: 26
Study: 17505460

Group type: EXPERIMENTAL
Intervention: Corticosteroids administration (antepartum or postpartum)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Corticosteroids administration
Number of subjects: 0
Study: 15848504

Group type: COMPARATOR
Intervention: Sirolimus (SRL) + Cyclosporine (CsA), n = 98
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL), n = 69
Number of subjects: 167
Study: 11950803

Group type: EXPERIMENTAL
Intervention: CO2 insufflation
Number of subjects: 240

Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 240
Study: 9466503

Group type: EXPERIMENTAL
Intervention: Ultrasound dilution (Transonics Hemodialysis Monitor, Transonics Systems Incorporated) (TRANS)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Differential conductivity (Hemodynamic Monitor, GAMBRO Healthcare Incorporated) (HDM)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Hematocrit dilution (Crit‐Line Monitor, In‐Line Diagnostics) (CRIT)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Comparison of Qa values
Number of subjects: 64
Study: 7881669

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 150 mg.kg‐1 in 250 ml 5% dextrose intravenously over 15 min
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo in 250 ml 5% dextrose intravenously over 15 min
Number of subjects: 38
Study: 2404433

Group type: EXPERIMENTAL
Intervention: Rynatan (8 mg chlorpheniramine tannate, 25 mg pyrilamine tannate, 25 mg phenylephrine tannate)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Rynatan
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study: 39233

Group type: EXPERIMENTAL
Intervention: 3 x 100 mg Betadrenol daily for three days
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 3 x 100 mg Betadrenol daily for ten days
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 31910822

Group type: EXPERIMENTAL
Intervention: Supreme laryngeal mask airway (SLMA) insertion
Number of subjects: 45

Group type: COMPARATOR
Intervention: ProSeal laryngeal mask airway (PLMA) insertion
Number of subjects: 45
Study: 30954304

Group type: EXPERIMENTAL
Intervention: Immunoglobulin plus ciclosporin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous immunoglobulin
Number of subjects: 0
Study: 28202770

Group type: EXPERIMENTAL
Intervention: Daptomycin (5 mg/kg for 12-17 years, 7 mg/kg for 7-11 years, 9 mg/kg for 2-6 years, 10 mg/kg for 12-23 months)
Number of subjects: 389

Group type: COMPARATOR
Intervention: Standard-of-care (SOC) treatment (primarily clindamycin or vancomycin)
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Daptomycin
Number of subjects: 389

Group type: COMPARATOR
Intervention: Standard-of-care (SOC) treatment
Number of subjects: 389
Study: 25611207

Group type: EXPERIMENTAL
Intervention: Prednisone (60 mg daily for 1 week)
Number of subjects: 0
Study: 22886783

Group type: EXPERIMENTAL
Intervention: Elevated CRP (≥2 mg/L)
Number of subjects: 2153

Group type: COMPARATOR
Intervention: No elevated CRP (<2 mg/L)
Number of subjects: 2153
Study: 21147190

Group type: EXPERIMENTAL
Intervention: Hedonic cues (association with yoghurt liking)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Sensory cues (association with sweetness or saltiness)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Subliminal cue presentations
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Supraliminal cue presentations
Number of subjects: 39
Study: 19440073

Group type: EXPERIMENTAL
Intervention: Testosterone replacement (200 mg of testosterone cypionate intramuscular injections every 10 days)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Testosterone replacement
Number of subjects: 23
Study: 16750472

Group type: COMPARATOR
Intervention: Pelvic floor muscle training (PFMT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Duloxetine after inadequate PFMT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Duloxetine alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study: 15823769

Group type: EXPERIMENTAL
Intervention: Zonisamide (400 mg/d)
Number of subjects: 37
Study: 11578887

Group type: EXPERIMENTAL
Intervention: 4 mg ondansetron (Group O)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: 10 mg metoclopramide (Group M)
Number of subjects: 164

Group type: COMPARATOR
Intervention: 10 mL normal saline (Group P)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Group O and Group M
Number of subjects: 164
Study: 15102384

Group type: EXPERIMENTAL
Intervention: Controlled-release oxycodone
Number of subjects: 100

Group type: COMPARATOR
Intervention: Controlled-release morphine
Number of subjects: 100
Study: 7930025

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO) at concentrations of 100-2000 ppb
Number of subjects: 6
Study: 3797170

Group type: EXPERIMENTAL
Intervention: Skin temperature controlled at 35.5 degrees C
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Skin temperature controlled at 36.5 degrees C
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Skin temperature controlled at 37.5 degrees C
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Optimal abdominal skin temperature control
Number of subjects: 18
Study: 30704522

Group type: EXPERIMENTAL
Intervention: Transplanted parathyroid glands at novel sites (group B)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Transplanted parathyroid glands at traditional sites (group A)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 280
Study: 27916406

Group type: EXPERIMENTAL
Intervention: mTBI (symptomatic participants)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: mTBI (asymptomatic participants)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 53
Study: 26008690

Group type: EXPERIMENTAL
Intervention: Low-dose decitabine (DAC) alone
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Low-dose decitabine (DAC) in combination with valproic acid (VPA)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Low-dose decitabine (DAC) in combination with all-trans retinoic acid (ATRA)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Low-dose decitabine (DAC) in combination with both VPA and ATRA
Number of subjects: 189
Study: 23530110

Group type: EXPERIMENTAL
Intervention: R-CVP
Number of subjects: 534

Group type: EXPERIMENTAL
Intervention: R-CHOP
Number of subjects: 534

Group type: EXPERIMENTAL
Intervention: R-FM
Number of subjects: 534
Study: 21270189

Group type: EXPERIMENTAL
Intervention: Exenatide once weekly (2 mg)
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: Sitagliptin (100 mg)
Number of subjects: 491

Group type: COMPARATOR
Intervention: Pioglitazone (45 mg)
Number of subjects: 491
Study: 19789970

Group type: EXPERIMENTAL
Intervention: Pulmonary vein antrum isolation (PVAI)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Antiarrhythmic and direct current cardioversion (A+DCCV)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Atrioventricular junctional ablation (AVJA)
Number of subjects: 1000
Study: 16839321

Group type: EXPERIMENTAL
Intervention: Tadalafil
Number of subjects: 367
Study: 15545541

Group type: EXPERIMENTAL
Intervention: Single-pass CO(2) laser skin resurfacing with cold-air cooling
Number of subjects: 8
Study: 11411653

Group type: EXPERIMENTAL
Intervention: 4 mg nicotine (Nicorette® chewing gum)
Number of subjects: 25
Study: 9121968

Group type: EXPERIMENTAL
Intervention: DDD pacing
Number of subjects: 30

Group type: COMPARATOR
Intervention: VVI pacing
Number of subjects: 30
Study: 7911147

Group type: EXPERIMENTAL
Intervention: 2 g cefoxitin
Number of subjects: 250

Group type: COMPARATOR
Intervention: 2 g piperacillin
Number of subjects: 250
Study: 3661948

Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Enflurane
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Thiopental
Number of subjects: 24
Study: 28603874

Group type: EXPERIMENTAL
Intervention: Long Rest Training (LRT, 10-s rest)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Short Rest Training (SRT, 3-s rest)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Both LRT and SRT
Number of subjects: 14
Study: 27827962

Group type: EXPERIMENTAL
Intervention: Cholecalciferol (5000 IU/week)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 60
Study: 25140958

Group type: EXPERIMENTAL
Intervention: Bedaquiline (400 mg once daily for 2 weeks, followed by 200 mg three times a week for 22 weeks)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 23810627

Group type: EXPERIMENTAL
Intervention: Couple-oriented HIV counselling session (COC)
Number of subjects: 1607

Group type: COMPARATOR
Intervention: Standard post-test HIV counselling
Number of subjects: 1607
Study: 20529368

Group type: EXPERIMENTAL
Intervention: Comprehensive assessment including in-home interview, self-administered questionnaire, medical/dental examination.
Number of subjects: 1152

Group type: EXPERIMENTAL
Intervention: Carotid ultrasonography
Number of subjects: 1152

Group type: EXPERIMENTAL
Intervention: Masticatory assessment using a colour-changeable chewing gum
Number of subjects: 1152
Study: 19049379

Group type: EXPERIMENTAL
Intervention: Insulin aspart
Number of subjects: 17

Group type: COMPARATOR
Intervention: Insulin lispro
Number of subjects: 17
Study: 12557453

Group type: EXPERIMENTAL
Intervention: Real contingent alpha/theta feedback training
Number of subjects: 2

Group type: COMPARATOR
Intervention: Mock feedback control condition
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Both groups (Real contingent a/t feedback and Mock feedback)
Number of subjects: 2
Study: 9641689

Group type: EXPERIMENTAL
Intervention: Low-dose lamifiban (1 microg/min)
Number of subjects: 2282

Group type: EXPERIMENTAL
Intervention: High-dose lamifiban (5 microg/min)
Number of subjects: 2282

Group type: EXPERIMENTAL
Intervention: High-dose lamifiban and heparin
Number of subjects: 2282

Group type: EXPERIMENTAL
Intervention: Low-dose lamifiban and heparin
Number of subjects: 2282

Group type: COMPARATOR
Intervention: Standard therapy (placebo and heparin)
Number of subjects: 2282
Study: 7979888

Group type: EXPERIMENTAL
Intervention: Psychotherapy (cognitive-behavioral relapse prevention)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Pharmacotherapy (desipramine hydrochloride)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Psychotherapy (supportive clinical management)
Number of subjects: 121
Study: 2481743

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 1192857

Group type: EXPERIMENTAL
Intervention: Phlebotomy (10 percent of blood volume)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham procedure (Control)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Phlebotomy
Number of subjects: 18

Group type: COMPARATOR
Intervention: Phlebotomy and Control
Number of subjects: 18
Study: 30476451

Group type: EXPERIMENTAL
Intervention: CDS-generated report cards
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Real-time CDS alerts
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Both feedback types (report cards and alerts)
Number of subjects: 108

Group type: COMPARATOR
Intervention: No feedback (baseline)
Number of subjects: 108
Study: 28851188

Group type: EXPERIMENTAL
Intervention: Nicorandil (10 mg orally before PCI and 15 mg/d for 3 days)
Number of subjects: 120
Study: 25389256

Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir 300/100 mg
Number of subjects: 118

Group type: COMPARATOR
Intervention: Darunavir/ritonavir 800/100 mg
Number of subjects: 118
Study: 23724021

Group type: EXPERIMENTAL
Intervention: BKSE1.0
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: BKSE0.5
Number of subjects: 138

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 138
Study: 21612894

Group type: EXPERIMENTAL
Intervention: 25 mg/kg/day amikacin
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: 30 mg/kg/day amikacin
Number of subjects: 99

Group type: COMPARATOR
Intervention: 15 mg/kg/day (historical standard dose)
Number of subjects: 99
Study: 18848318

Group type: EXPERIMENTAL
Intervention: Vitamin A (retinyl palmitate) 0.05% eye drops, four times daily
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Cyclosporine A 0.05% eye drops, twice daily
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group treated with preservative-free artificial tears alone
Number of subjects: 150
Study: 16817814

Group type: EXPERIMENTAL
Intervention: Cortisol (0.15 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Corticosterone (0.15 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Corticosterone (0.04 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 0
Study: 15489467

Group type: EXPERIMENTAL
Intervention: Diet changes (percent change in percentage kilocalories from carbohydrate)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Diet changes (percent change in fruit/100% juice)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Physical activity changes (percent change in minutes of moderate‐to‐vigorous activity)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Moderate‐to‐vigorous physical activity
Number of subjects: 127
Study: 11313301

Group type: EXPERIMENTAL
Intervention: Intravenous cyclosporine, 4 mg x kg(‐1) x day(‐1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Methylprednisolone, 40 mg/day
Number of subjects: 30
Study: 9257745

Group type: EXPERIMENTAL
Intervention: Cefepime
Number of subjects: 99

Group type: COMPARATOR
Intervention: Piperacillin plus Gentamicin (P+G)
Number of subjects: 99
Study: 8292833

Group type: EXPERIMENTAL
Intervention: Traditional African herbal concoction (placebo)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Commercial Western-style medicine (placebo)
Number of subjects: 21
Study: 30986113

Group type: EXPERIMENTAL
Intervention: Closed-loop system for diabetes management
Number of subjects: 24
Study: 29500567

Group type: EXPERIMENTAL
Intervention: Target-CF 15 g (G1)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Target-CF 10 g (G2)
Number of subjects: 106

Group type: COMPARATOR
Intervention: CF concealed from operator (G3)
Number of subjects: 106
Study: 27396474

Group type: EXPERIMENTAL
Intervention: Thin-walled introducer needle
Number of subjects: 414

Group type: COMPARATOR
Intervention: Catheter-over-needle technique
Number of subjects: 414
Study: 24616420

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgery + diet/exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diet/exercise alone
Number of subjects: 0
Study: 21880562

Group type: EXPERIMENTAL
Intervention: Exposure to thin ultra-fit models
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Exposure to normal weight athletic models
Number of subjects: 138

Group type: COMPARATOR
Intervention: Control condition (neutral objects)
Number of subjects: 138
Study: 20554709

Group type: EXPERIMENTAL
Intervention: Phosphocreatine (PCr) recovery evaluated by (31)phosphorous-MRS after submaximal exercise
Number of subjects: 121
Study: 18385420

Group type: EXPERIMENTAL
Intervention: CYP4A11 8590CC genotype
Number of subjects: 732
Study: 16939743

Group type: EXPERIMENTAL
Intervention: IVIG plus corticosteroid (IVIG+PSL)
Number of subjects: 178

Group type: COMPARATOR
Intervention: IVIG
Number of subjects: 178
Study: 12660684

Group type: EXPERIMENTAL
Intervention: HeartBar (3.3 g L-arginine, consumed twice daily for 2 weeks)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo bar (consumed twice daily for 2 weeks)
Number of subjects: 47
Study: 10731454

Group type: EXPERIMENTAL
Intervention: Nursing telephone intervention (one or two calls per week from 24th to 37th week of gestation)
Number of subjects: 1554

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1554
Study: 9365345

Group type: EXPERIMENTAL
Intervention: Paraspinal mapping (PM) electromyography (EMG) protocol
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Paraspinal mapping (PM) combined with lower extremity (LE) EMG
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Paraspinal mapping (PM)
Number of subjects: 114